Today: 9 June 2026
Diageo share price climbs in London as Barclays, Jefferies stick with Buy calls ahead of Feb 25 results
22 January 2026
1 min read

Diageo share price climbs in London as Barclays, Jefferies stick with Buy calls ahead of Feb 25 results

London, Jan 22, 2026, 09:33 GMT — Regular session

Diageo shares climbed roughly 0.5% to about 1,681 pence in early London trading Thursday, continuing a bounce that pushed the stock up 2.6% the previous day. Despite this, the world’s biggest spirits producer remains down around 31% over the last year, making it vulnerable to any signs of stabilizing demand.

This shift is significant as investors seek stability before the upcoming earnings reports — not lofty forecasts, but signs that declines in major markets are slowing. Several analyst notes this week have also highlighted how much negative news might already be baked into prices.

Diageo released an “aide memoire” on Wednesday ahead of its interim results, reaffirming its fiscal 2026 outlook without offering fresh guidance or commentary on current trading. The company expects organic net sales — which exclude currency effects and acquisitions — to remain flat or dip slightly. Organic operating profit is forecast to grow in the low-to-mid single digits, supported by cost savings from its “Accelerate” programme, alongside roughly $3 billion in free cash flow for the year. www.diageo.com

Analyst calls remained mostly positive. Barclays’ Laurence Whyatt stuck with a Buy rating and held the target price steady at 2,550 pence. Jefferies’ Edward Mundy also maintained a Buy rating, setting a 2,000 pence target—both comfortably above the current share price, according to MarketScreener summaries.

Positive signals from India lifted sentiment around the group’s emerging-market holdings. Diageo-controlled United Spirits posted a 12% jump in quarterly profit, Reuters said, driven by steady demand for premium liquor. Its “prestige & above” category expanded 8.2%, while the more affordable “popular” segment saw a decline. Reuters

On a separate earnings call, Diageo India’s managing director Praveen Someshwar told analysts he’s spotting “consumption green shoots,” though he warned policy hurdles remain in major states like Maharashtra and Telangana, according to The Economic Times. The Economic Times

London investors now face a key question: can premium strength counterbalance weaker volume in the more price-sensitive segments? Revenue can hold steady on price and mix, even if fewer bottles sell. But that won’t last if discounting makes a comeback.

The trade isn’t one-sided. If U.S. spirits demand slips further or China hits a rough patch, volumes could take a hit. That would push Diageo to lean on promotions, squeezing margins just as it aims to meet its cost and cash goals.

Traders keep an eye on how fast the company converts inventory into cash, trying not to rely too much on discounts. This balance first affects working capital and then, more subtly, free cash flow.

Diageo’s interim results for the six months ending Dec. 31 are set for Feb. 25. Investors will be looking closely for updates on demand trends and whether the firm remains on course with its fiscal-year cash flow and profit targets.

Stock Market Today

  • Aker BP Share Price Surges Amid Valuation Debate
    June 9, 2026, 11:54 AM EDT. Aker BP (OB:AKRBP) shares climbed to NOK347.7, marking a 55.05% total shareholder return over one year, outperforming peers in Norway's energy sector. Despite this momentum, the stock trades at an 8.6% premium over a fair value of NOK320.11, raising questions about valuation. The company aims to sustain production above 500,000 barrels per day past 2030, backed by projects like Yggdrasil and Johan Sverdrup, supporting revenue growth. Yet, potential risks include higher emissions costs and delays in key developments. Analysts offer cautious pricing, but a discounted cash flow (DCF) model from Simply Wall St suggests a much higher intrinsic value of NOK1,769.75, indicating significant undervaluation. Investors face a valuation divide between conservative targets and optimistic cash flow projections.

Latest articles

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

9 June 2026
Paranovus Entertainment shares soared 620% to $6.76 after filing to potentially sell up to $195 million in new stock—an amount far exceeding its $7.14 million market cap—raising major dilution risks for investors as the company eyes acquisitions but warns that future share sales could pressure the stock price or threaten operations.
Coupang Stock Gains as Privacy Ruling Approaches

Coupang Stock Gains as Privacy Ruling Approaches

9 June 2026
Coupang shares jumped 2% to $15.49, outperforming a falling market, as investors braced for South Korea’s privacy regulator to decide June 10 on possible sanctions over a data breach exposing 33.6 million records—a ruling that could trigger fines up to 3% of sales and impact the stock’s recovery.
AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

9 June 2026
AEP lifted its five-year capital plan to $78 billion after signing 7 gigawatts of new large-energy project agreements, with 90% of 63 gigawatts of expected incremental load by 2030 tied to data centers; shares recently traded at $127.27, up 26.9% over 52 weeks, with analysts’ mean price target at $142.76, as investors weigh execution risks and a new data-center rate structure.
Dow climbs in New York, but gains may stall

Dow climbs in New York, but gains may stall

9 June 2026
Dow jumps 154.87 points as tech rebounds and oil prices drop, with chipmakers like Intel and Broadcom up sharply; investors brace for Wednesday’s key inflation data and next week’s Fed meeting, which could sway rate expectations and market direction.
U.S. Stocks Hit Records This Week — Why the S&P 500 and Nasdaq Rally Survived the Oil Shock

Dow Up While Nasdaq Dips; AI Rally Meets Inflation Data

9 June 2026
Nuvalent soared after GSK agreed to buy the cancer drug developer for $10.6 billion in cash, valuing shares at $124—a 40% premium to Monday’s close—while investors awaited Wednesday’s key inflation data that could impact market direction and tech stock stability.
BT share price jumps as Openreach steps up copper switch-off — UBS still says “sell”
Previous Story

BT share price jumps as Openreach steps up copper switch-off — UBS still says “sell”

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX
Next Story

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Go toTop